Multipotential stromal cell abundance in cellular bone allograft: Comparison with fresh age-matched iliac crest bone and bone marrow aspirate by Baboolal, TG et al.
Regen. Med. (Epub ahead of print) ISSN 1746-0751
part of
10.2217/RME.14.17 © 2014 Future Medicine Ltd
Research Article
Multipotential stromal cell abundance in 
cellular bone allograft: comparison with 
fresh age-matched iliac crest bone and 
bone marrow aspirate
Aim: To enumerate and characterize multipotential stromal cells (MSCs) in a cellular bone 
allograft and compare with fresh age-matched iliac crest bone and bone marrow (BM) 
aspirate. Materials & methods: MSC characterization used functional assays, confocal/
scanning electron microscopy and whole-genome microarrays. Resident MSCs were 
enumerated by flow cytometry following enzymatic extraction. Results: Allograft 
material contained live osteocytes and proliferative bone-lining cells defined as 
MSCs by phenotypic and functional capacities. Without cultivation/expansion, the 
allograft displayed an ‘osteoinductive’ molecular signature and the presence of CD45-
CD271+CD73+CD90+CD105+ MSCs; with a purity over 100-fold that of iliac crest bone. In 
comparison with BM, MSC numbers enzymatically released from one gram of cellular 
allograft were equivalent to approximately 45 ml of BM aspirate. Conclusion: Cellular 
allograft bone represents a unique nonimmune material rich in MSCs and osteocytes. 
This osteoinductive graft represents an attractive alternative to autograft bone or 
composite/synthetic grafts in orthopedics and broader regenerative medicine settings.
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More than two million bone graft procedures 
are performed annually worldwide to repair 
bone defects in orthopedics, neurosurgery 
and dentistry [1]. Autograft bone remains the 
‘gold standard’ for bone replacement because 
it contains the essential components needed 
for successful bone repair when placed in a 
mechanically stable environment: osteocon­
ductive scaffold, osteogenic cells and osteo­
inductive growth factors such as the bone 
morphogenetic proteins (BMPs) [2]. Auto­
graft is commonly obtained from patient’s 
iliac crest (IC), however it has known disad­
vantages including additional surgery, lim­
ited supply, donor­site morbidity, pain and 
potential infection [3]. In spinal surgery, and 
particular for minimally invasive techniques, 
alternative strategies including BMP2­laden 
matrices [4,5], synthetic grafts [5,6] or local 
delivery of autologous bone marrow (BM) 
aspirate [5] have been employed. Recombi­
nant BMP2 use has recently raised safety 
concerns due to potential increased risks of 
adverse events including inflammation and 
possible new malignancy [7,8], while synthetic 
calcium phosphate grafts can only provide 
the osteoconductive scaffolding component. 
Local (BM) aspirate injections on the other 
hand, typically have low osteogenic cell 
yields and poor cellular attachment to scaf­
folds, which may lead to only a few osteo­
genic cells remaining at the intended site 
of repair [9]. As a result, new developments 
have emerged such as so called ‘composite’ 
or ‘hybrid’ grafts [10] that compose of either 
a synthetic scaffold [11–13] or an allograft [14] 
intraoperatively ‘loaded’ with autologous BM 
aspirate or volume­reduced BM ’concentrate’.
In general, the use of allografts in bone 
repair have been impeded by perceived safety 
concerns with regards to disease transmis­
sion and lack of osteogenic properties similar 
to synthetics [15]. However, improved allo­
graft safety has now been achieved through 
advanced donor screening and the use of 
highly sensitive viral nucleic acid testing [15]. 
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The lack of osteogeneic cells in typical allograft, on 
the other hand, has always resulted from the ‘harsh’ 
tissue processing necessary to completely remove the 
donor cells creating an acellular material. However, in 
the last 10 years the concept of a ‘viable’ cellular bone 
allograft has emerged, which incorporates the selective 
removal of the immune cell component from the graft, 
while preserving the osteogenic, nonimmune cells. In 
fact, the first such material, Osteocel®, has been used 
clinically since 2005 for bone regeneration for spine, 
maxillofacial and long­bone applications [16–20], with 
successful outcomes and no graft­associated adverse 
events recorded. Osteocel graft material is obtained 
from cadaveric cancellous bone, in which selective 
cell preservation is achieved by tissue processing and 
washing, with the addition of demineralized cortical 
bone before the combination is cryopreserved. 
Very little has been published about the relative 
number and vitality of osteogenic cells remaining 
on ‘viable’ cellular allografts post­cryopreservation. 
A limited number of studies published to date have 
demonstrated the presence of osteogenic multipoten­
tial stromal cells (MSCs) in Osteocel; however, this 
was achieved only following extensive cellular cultiva­
tion and expansion [20,21]. The aim of this study was 
therefore to document, enumerate and phenotypically 
characterize MSCs in this cellular allograft material 
without culture expansion (as would be seen clini­
cally). We also investigated and compared the abun­
dance of native MSCs in the cellular allograft with that 
of ‘gold­standard’ freshly obtained IC bone graft and 
BM aspirate. 
Materials & methods
Patient samples
A total of 16 different Osteocel lots (NuVasive, Inc., 
CA, USA) were analyzed. Each lot was from a differ­
ent tissue donor: ten for flow cyto metry, tissue culture, 
confocal and scanning electron microscopy (1 and 
2 cm3, median donor age 35 years, range 23–41 years) 
and six for whole­genome microarray (5 cm3, median 
donor age 31 years, range 24–39 years). Control sam­
ples included age­matched BM aspirate and IC bone; 
additionally, cancellous bone from excised femo­
ral heads was used for method optimization of flow 
cytometry (n = 6 donors). 
BM aspirates were carefully drawn from the IC of 
acute trauma patients or patients undergoing elective 
orthopedic surgery for metalwork removal (n = 16, 
median age 34, range 24–40). For BM aspiration, 
consistency was assured in terms of surgeon (same 
person for all samples), aspirate location (anterior IC), 
needle (Stryker 306–111, 11­gauge, bevel tipped tro­
car, MI, USA), volume of aspirate (20 ml) and draw 
method (single 20 ml draw). Control IC cancellous 
bone samples (average weight 0.2 g) were collected 
from the IC of trauma patients undergoing pelvic 
reconstruction (n = 14 donors, median age 40 years, 
range 23–48). All patients had no underlying disease. 
The sample collection protocols were approved by 
National Research Ethics committee.
Osteocel sample processing for explant 
& microscopy studies
Osteocel allograft consists of ‘viable’ cancellous bone 
fragments and acellular/nonviable demineralized bone 
matrix (DBM) particles (DBM processed from cortical 
bone of the same donor). Osteocel samples were thawed 
in accordance with manufacturer’s instructions in a 
37°C water bath and washed with 10 ml of phosphate 
buffered saline (PBS, Invitrogen, Paisley, UK). The 
larger cancellous bone fragments were separated from 
smaller DBM particles using a sterile 850­µm metal 
sieve (Fisher, Loughborough, UK). Subsequently, can­
cellous bone fragments were transferred into 100 mm 
culture dish and washed with 10 ml of PBS. Explant 
cultures were initiated by replacing PBS with 15 ml of 
nonhematopoietic expansion medium (Miltenyi Bio­
tec, Bisley, UK). Dishes were fed twice­weekly with 
half­media changes until reaching confluence (termed 
passage 0 [p0]); subsequently, cells were detached 
using 0.05% trypsin­EDTA (Invitrogen), re­seeded 
at a density of 104 cells/cm2 and further expanded for 
two passages for functional assays and flow cytometry 
ana lysis. 
In all the remaining experiments, cancellous bone 
fragments were analyzed immediately following sep­
aration from DBM particles (termed Day 0 Osteo­
cel), by flow cytometry, confocal or environmental 
scanning electron microscopy (ESEM) and histology. 
Samples intended for ESEM were fixed (3.7% forma­
lin/PBS) and stored at room temperature in PBS until 
use. Confocal microscopy was used for the detection 
of viable and nonviable cells by staining nonfixed sam­
ples with the live/dead viability stains Calcein AM 
and ethidium homodimer­1 (Invitrogen), according to 
manufacturer recommendations. Images were taken of 
hydrated samples using a 20× water dipping objective. 
Optical sections were made 3 µm apart using a Leica 
SP2 TCS laser scanning microscope (Leica, Bucking­
hamshire, UK); the bone surface was imaged using 
reflected light (excitation at 488 nm and emission 
between 479–498 nm). ESEM was used to visualize 
cell coverage and subsequent cell growth on scaffold 
surface and was performed on hydrated samples using 
a Hitachi S­3700N variable pressure scanning electron 
microscope (Hitachi, Berkshire, UK), as previously 
described [22]. Histology slides were prepared following 
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routine demineralization with formic acid. Hemat­
oxylin and eosin staining was performed on 5 µm 
sections using standard histology protocols.
Osteocel sample processing for flow cytometry 
to detect & quantify native MSCs 
To enumerate and characterize MSCs in Day 0 Osteo­
cel, we used the CD271 marker that is specific for 
uncultured intra­osseous MSCs [23–28], in combina­
tion with CD45 as a negative marker. Bone fragments 
were weighed, washed thoroughly with PBS, placed in 
0.5 ml 0.25% collagenase (Stem Cell Technologies, 
Grenoble, France) per 0.2 g of tissue and digested 
for 4 h with gentle agitation to obtain single­cell sus­
pensions [27]. The fragments were weighed in order 
to calculate the total number of MSCs per gram of 
bone. The liquid fraction containing cells was filtered 
through a 70 µm filter (BD Biosciences, Oxford, 
UK), centrifuged (400 × g, 5 min), washed in PBS 
and diluted in FACS buffer (PBS, 0.5% bovine serum 
albumin and 2 mM EDTA) to give a final staining 
volume of 200 µl. Nonspecific binding was blocked 
using 10 µl FCR blocking reagent (Miltenyi Biotec) 
and incubated for 10 min before staining with CD90­
FITC, CD105­PE (both from Serotec, Kidlington, 
UK), CD73­PerCP­Cy5.5, CD45­PE­Cy7 (both from 
BD Biosciences), CD271­APC (Miltenyi Biotec), 
aqua fluorescent dye and Calcein AM from the live/
dead violet viability/vitality kit (Invitrogen), all at 
manufacturer’s recommended concentrations. CD73, 
CD90 and CD105 were used to confirm the MSC 
identity of CD45­CD271+ cells in compliance with the 
International Society of Cell Therapy (ISCT) criteria 
for MSCs [29]. Cells were incubated for 30 min on ice 
in the dark before adding 50 µl of thoroughly mixed 
CountBright beads (Molecular Probes/Life Technol­
ogies, Paisley, UK) to permit absolute cell quanti­
fication. The sample volume was made up to 400 µl 
with FACS buffer before analyzing on an LSRII flow 
cytometer using FACSDiva™ 7 software (Beckton 
Dickenson, NJ, USA).
The frequency of CD45­CD271+ MSCs was calcu­
lated in relation to total live cells. The expression of 
CD73, CD105 and CD90 was calculated on gated 
CD45­CD271+ MSCs, isotype controls were purchased 
from BD Biosciences. Additionally, the same antibody 
panel was used on Osteocel digests (but without the 
addition of CountBright beads) and acquired using 
ImageStream® flow cytometer (Amnis, Seattle, Wash­
ington DC, USA); which allowed the simultaneous 
assessment of CD45­CD271+ MSC morphology and 
phenotype.
The total number of enzymatic­released CD45­ 
 CD271+ MSCs per gram of Osteocel (n = 5) was deter­
mined as follows. First, the total number of MSCs 
in the staining volume was calculated in relation to 
total CountBright beads according to manufacturer’s 
instructions and adjusted to give the total number of 
cells in the sample. Subsequently, this count was con­
verted to the total number MSC per gram of tissue for 
each particular Osteocel sample, taking into account 
the weight of Osteocel bone before digestion. 
Analysis of MSC-related activity in Osteocel 
using whole genome microarray ana lysis
Osteocel samples were allowed to thaw; cryoprotectant 
was removed and the bone chips were rinsed with 5 ml 
PBS. Total RNA was isolated using a column­based 
extraction protocol with a DNase I step (Ambion®/Life 
Technologies, NE, USA); the purity and quantity 
of total RNA was determined using a NanoDrop 
ND­1000 UV spectrophotometer (NanoDrop Prod­
ucts, DE, USA) and the integrity of RNA was qual­
ified using Agilent Bioanalyzer 2100 (Agilent Tech­
nologies, CA, USA). Control RNA samples of adult 
human osteoblast (406­R25a) and adult human der­
mal fibroblast (106­R25a) cell lines (Cell Applications, 
Inc., CA, USA) were treated similarly.
Total mRNA (100 ng per sample) was used for 
preparation of biotin­labeled targets using an Illu­
mina TotalPrep™ kit (Ambion Inc., TX, USA) with 
one round of amplification. Biotin­labeled cRNA was 
used to probe HumanHT­12 v3 Expression BeadChips 
(Illumina, Inc., CA, USA). Hybridization, washing, 
and scanning of the arrays were performed according 
to the manufacturer’s instructions. Illumina BeadScan 
software was used to produce data files for each array; 
raw data were extracted using Illumina BeadStudio 
software v3. Following quality assessment, data on 
each array were summarized into raw intensity values, 
gene identifiers and corresponding probe IDs. Com­
parison of the differential expression patterns between 
Osteocel samples and the control cell lines with a data­
set obtained from MSCs and their progeny [30] resulted 
in a list of markers of particular interest based on their 
known functions in MSC, bone development and 
physiology (listed in Table 1). 
Analysis of Osteocel-MSC functionality 
following explant culture & low passage 
expansion
To confirm the identity of Osteocel­resident MSCs, 
flow cytometry on passage 2–3 expanded cells was per­
formed using full ISCT antibody panel [29]; consisting of 
CD73­PE, CD90­PE, CD105­PE, CD14­PE, CD19­
FITC, CD34­PcP, CD45­PE­Cy7 and HLADR­AP­
C­H7 (all antibodies from BD Biosciences) with 
4 ,´6­diamidino­2­phenylindole (DAPI) as a viability 
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marker [31]. To confirm MSC functionality, mesenchy­
mal tri­lineage differentiation assays were performed in 
standard conditions as previously described [27]. 
The immunosuppressive capacity of Osteocel­MSCs 
was tested in co­culture with CD4+ T cell responders 
(Tresp). Tresp were purified from peripheral blood 
mononuclear cells by depletion of non­CD4+ cells 
(CD4+ T cell isolation kit II, Miltenyi Biotec) and 
labeled with the carbocyfluorescein succini midyl ester 
dye analogue, CellTrace™ Violet (Invitrogen), in order 
to track Tresp cell divisions following stimulation. 
Tresp proliferation was stimulated using MSC Suppres­
sion Inspector containing Anti­Biotin MACSiBead™ 
particles preloaded with biotinylated CD2, CD3, and 
CD28 antibodies (Miltenyi Biotec). Prior to co­culture, 
p2 Osteocel­MSCs were irradiated (30 Gy) to prevent 
further proliferation in co­culture with Tresp. Co­cul­
tures were established in flat­bottomed 96­well plates 
using the following MSC:Tresp ratios: 1:1, 1:2, 1:4 and 
1:8 [32]. The total number of Tresp/well was kept con­
stant (105/well), and the number of MSCs was adjusted 
according to specific MSC:Tresp ratios. Control wells 
included: labeled but not stimulated Tresp (no stim­
ulation control) and labeled+stimulated Tresp with­
out MSCs (No MSC control) [32]. Co­cultures were 
maintained in Glutamax™ RPMI 1640 (Invitrogen) 
supplemented with 10% human AB serum (Sigma, 
Dorset, UK) for 5 days. 
The inhibition of Tresp proliferation under the 
influence of MSCs was measured using flow cytometry 
by analyzing the pattern of CellTrace Violet dilution 
on Tresp cells [33]. For accurate gating on Tresp cells, 
CD90­FITC (Serotec) and CD45­PE­Cy7 (BD Bio­
sciences) were used to exclude potential contamination 
with MSCs; 7­AAD was used as a viability marker. 
Tresp divisions/generations were calculated using 
Table 1. Molecular analysis of Osteocel® in comparison to dermal fibroblast and osteoblast cell lines.
Full name Gene code Versus 
osteoblasts†
Versus 
fibroblasts†
Osteopontin, transcript variant 2 SPP1 22.3 119.7
Osteopontin, transcript variant 1 SPP1 26.0 64.2
Chemokine (C-X-C motif) receptor 7, transcript variant 1 CXCL7 29.4 63.3
S100 calcium binding protein A8 S100A8 88.3 62.8
Transferrin TF 30.8 54.3
Insulin-like growth factor binding protein 3, transcript variant 1 IGFBP3 1.5 38.1
Bone g-carboxyglutamate (gla) protein (osteocalcin) BGLAP 26.6 36.8
Vascular cell adhesion molecule 1, transcript variant 1 VCAM1 7.8 25.9
S100 calcium binding protein A12 S100A12 16.3 22.4
Chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1), transcript 
variant 1
CXCL12 -3.3 21.2
Frizzled-related protein FRZB 15.4 17.00
S100 calcium binding protein A9 S100A9 125.0 16.2
Bone morphogenetic protein 2 BMP2 22.5 12.4
Integrin-binding sialoprotein (bone sialoprotein, bone sialoprotein II) IBSP 9.0 12.3
Alkaline phosphatase, liver/bone/kidney ALP 2.0 11.9
Distal-less homeobox 5 DLX5 3.8 11.2
Homo sapiens parathyroid hormone receptor 1 PTHR1 7.7 8.3
Bone morphogenetic protein 6 BMP6 13.2 5.5
Homo sapiens jagged 1 (Alagille syndrome) JAG1 -1.9 5.2
Homo sapiens gap junction protein, alpha 1, 43 kDa (connexin 43) GJA1 2.8 4.6
Runt-related transcription factor 2, transcript variant 1 RUNX2 2.0 2.2
Sp7 transcription factor, osterix SP7 2.1 2.1
Distal-less homeobox 3 DLX3 1.9 2.0
Gremlin 1, cysteine knot superfamily, homolog (Xenopus laevis) GREM1 -10.5 -3.8
†Fold changes based on mean values (n = 6 Osteocel Plus lots).
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ModFit software version 3.2 (Verity Software House, 
Topsham, ME. USA). MSC suppression was calculated 
using relative division index as previously described 
[34]; and calculated as an ‘average’ Tresp generation 
(calculated as a geometric mean) in MSC­containing 
wells and normalized to the ‘average’ Tresp generation 
in no MSC control (100%) [34].
Processing & ana lysis of control samples IC 
bone & BM aspirate
IC bone fragments were washed in PBS, weighed 
and treated with collagenase to remove the cells, 
as described for Osteocel samples (above); the 
CD45­CD271+ MSC abundance per gram of bone 
was calculated similarly. The remaining untreated IC 
bone fragments were used for histology and ESEM 
microscopy. MSC enumeration in BM aspirates was 
performed as previously described [35]. Briefly, 50 µl 
of BM aspirate was incubated with CD45­PE­Cy7, 
CD73­PE and CD271­APC. Erythrocytes were lysed 
using 2 ml ammonium chloride solution (168 mM 
NH
2
Cl
2
, 10 mM KHCO
3
 and 1 mM EDTA) con­
taining 0.5 µg/ml DAPI (Sigma). Similar to Osteo cel­
MSC absolute counting protocol, counting beads were 
added to allow absolute MSC quantification per one 
ml of aspirate. Data were collected using LSRII and 
analyzed using FACSDiva software version 7.
Statistical ana lysis
The Mann–Whitney nonparametric test was used to 
compare MSC frequencies and their absolute numbers 
in Day 0 Osteocel, control IC bone and BM aspirate. 
Statistical significance was defined as P < 0.05. All 
statistics were calculated using SPSS® Version 21. 
Results
Cellular allograft contains functionally 
competent MSCs 
Our first aim was to confirm and extend previous find­
ings [20,21] indicating MSC ‘outgrowth’ in Osteocel 
explant cultures. Consistent with previous findings, 
we observed plastic­adherent, spindle­shaped cells 
emanating from Osteocel fragments that were capable 
of further expansion with good preservation of their 
fibroblastic morphology (Figure 1A). Osteocel­derived 
cultures fulfilled the minimal criteria for MSCs as 
defined functionally (Figure 1B) and phenotypically 
(Figure 1C) [29]. This was evident by the uniform pos­
itivity of Osteocel­derived cultures for MSC markers 
CD73, CD90 and CD105, and the lack of expression 
for hematopoietic­lineage markers such as CD45, 
CD19 and CD14.
Immunomodulation capacity has emerged as an 
important clinically relevant feature of MSCs [32]. 
We used multiparameter flow cytometry to accurately 
identify Tresp in co­cultures with different amounts 
of p2 Osteocel­MSCs (Figure 1D) and observed robust 
inhibition of Tresp proliferation (Figure 1E). In the 
absence of MSCs, MACSiBead­stimulated Tresp cells 
have undergone on average eight divisions in 5 days; 
this was inhibited to a maximum of three divisions at 
MSC:Tresp ratio of 1:1 (Figure 1E). This inhibitory 
effect was MSC dose­dependent, that is, increased 
with increasing numbers of MSCs/well (from ratios 
1:8 to 1:1) (Figure 1F). 
Altogether these data confirmed the outgrowth of 
MSCs from Osteocel explant cultures, indicating the 
presence of viable culture­initiating MSCs in the orig­
inal bone fragments. Furthermore, these experiments 
showed, for the first time, strong immunosuppressive 
capacity of Osteocel­MSCs.
Cellular allograft displays MSC- & osteoblast-
related signaling activity by microarray ana lysis
Since the immune cell component (lymphocytes and 
myelomonocytic lineage cells) is removed from Osteo­
cel cancellous bone by selective washes, any viable 
cells remaining associated with the allograft could be 
predicted to represent stromal lineage cells strongly 
attached to or embedded in bone. These could encom­
pass MSCs, osteoprogenitors, preosteoblasts and 
osteoblasts, osteocytes, preadipocytes/mature adipo­
cytes, as well as bone­resorbing osteoclasts. To detect 
any steady­state MSC­related signaling activity occur­
ring in Osteocel, we used whole human genome array 
technology and compared gene expression in Osteo­
cel lyzates with control osteoblast and fibroblast cell 
lines (latter used as negative controls for MSCs) [36]. 
Analysis revealed over 23 osteogenic and MSC­related 
genes that were differentially expressed by the Osteo­
cel samples at a level that was considered significant 
(greater­than or less­than a twofold change) [36]; the 
results are summarized in Table 1. 
Many of the osteogenic genes were up­regu­
lated, including those encoding osterix, osteocalcin, 
osteopontin, CXCL12 and bone/liver/kidney alkaline 
phosphatase, which were previously described by us 
and others as highly­specific for uncultured BM MSCs 
[36–38]. IGFPB3 was approximately 30­fold higher in 
Osteocel cell lyzates compared with dermal fibrob­
lasts, parallel to our previous data using MSCs [36]. 
Similar trends were found for FRZB/soluble frizzled­
related protein 3, connexin 43 and jagged 1, all highly 
specific for uncultured MSCs [36,37], with other evi­
dence indicating their expression in preosteoblasts [39] 
or bone­lining cells [40]. 
GREM1, an inhibitor of BMP signaling [41,42] 
was expressed at a lower level in Osteocel than either 
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osteoblasts or fibroblasts; potentially allowing for 
increased osteoinductive BMP signaling. The gene 
expression of BMP2 was also 22.5­ and 12.4­fold higher 
in Osteocel lyzates compared with both osteoblasts and 
fibroblasts, respectively (Table 1). Altogether, these data 
revealed strong MSC­ and osteoblast­related signaling 
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Figure 1. Phenotypic and functional characterization of cells grown from Osteocel® explant cultures. 
(A) Proliferative and (B) differentiation capacities, chondrogenesis and adipogenesis were assessed on day 21 
post-induction by Toluidine Blue or Oil Red-O staining, respectively. Osteogenesis was assessed by alkaline 
phosphatase staining on day 14 post-induction; original magnification of microphotographs ×100 and ×40 
for chondrogenesis. (C) Phenotypic characterization of Osteocel-derived cells confirming their identity as 
multipotential stromal cells (MSCs; n = 3 Osteocel lots). Gray filled histograms indicate isotype control staining. 
(D–F) Immunosuppressive capacity of Osteocel-MSCs in co-culture with T cell responders (Tresp) CD4+ T cells. 
(D) Gating strategy for Tresp cell employing initial gating for live cells followed by exclusion of MSCs and final 
gating on the CD4+ population. (E) Histograms indicating proliferation patterns of Tresp co-cultured at ratios 1:1 
to 1:4 with MSCs (a representative donor, colors represent cell doublings). (F) Inhibition of Tresp proliferation 
measured as relative division index normalized to no MSC control (n = 4 Osteocel lots, 1:1 to 1:8 ratios). Error 
bars represent SD. 
FI: Fluorescence intensity; MSC: Multipotential stromal cell; SSC: Side scatter.
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activity in Osteocel indicating steady­state functionality 
(at the transcriptional level) of these cells in situ.
Cellular allograft contains viable bone-lining 
cells & osteocytes 
We next performed microscopic ana lysis to investigate 
the potential location of MSCs resident in Osteocel. 
The depletion of hematopoietic BM was clearly evident 
on histological sections of Osteocel (Figure 2A) com­
pared with control IC bone (Figure 2B). In Osteocel, 
cell presence was detected in bone lacuni (osteocytes, 
Figure 2A, white filled arrows) and within bone pores 
(Figure 2A, black filled arrow). Bone­lining cells and 
a stromal cellular network was preserved in many 
fragments studied (Figure 2A, black filled arrows).
Confocal microscopy revealed the existence of live 
(as well as some dead) cells on Osteocel surface, which 
were primarily located in bone crevices (Figure 2C); this 
was consistent with histology data (Figure 2A). Digital 
removal of bone surface’s reflected light indicated the 
presence of more live cells underneath the bone surface, 
suggesting that osteocytes were also viable (Figure 2D). 
High numbers of osteocytes connected with canan­
iculi could also be seen by inverted light microscopy 
(Figure 2E), with cananiculi clearly visible at higher 
magnifications (Figure 2F, white filled arrows).
Because osteocytes are strongly embedded in bone 
matrix, we reasoned that only the bone­lining com­
partment could harbor MSCs giving rise to Osteocel 
outgrowth cultures. We next used ESEM and com­
pared the abundance of stromal cells on Osteocel with 
that of age­matched IC bone (Figure 3, top panels). 
Day 0 Osteocel fragments were notably less cellular 
than control bone. This was expected, as a conse­
quence of Osteocel’s immunodepletion processing 
procedure to remove the hematopoietic lineage cells 
[21] and consistent with histology data (Figure 2A & 2B).
We next explored in situ cell growth and coloniza­
tion of Osteocel and control bone by incubating frag­
ments in culture for 21 days prior to ESEM imaging 
(Figure 3, middle and bottom panels). On day 21 of 
culture, stromal cell layers bridging the bone pores 
were observed in both Osteocel and control bone 
(Figure 3, middle panels). These cells occupied empty 
spaces within bone pores and were anchored to the 
bone via clearly visible attachment points (Figure 3, 
bottom panels). 
Altogether our microscopy study indicated the pres­
ence of viable osteocytes and bone­lining cells in Osteo­
cel; furthermore, bone­lining cells (or a fraction of) 
were able to proliferate in situ prior to their egress onto 
the plastic and subsequent formation of 2D explant 
cultures. This established a potential topography of 
Osteocel­MSCs near to, or at the bone surface. This 
was in agreement with previous publications show­
ing the bone­lining (in addition to their perivascular) 
topography of MSCs in human bone [28,38].
Cellular allograft contains increased 
proportions & large numbers of viable 
CD45-CD271+ MSCs 
The next set of experiments was designed to identify 
and quantify Osteocel­MSCs following their enzy­
matic release from the bone surface (i.e., prior to any 
cell culture) using flow cytometry. For this, we first 
refined the flow cytometry method for enumeration of 
CD45­CD271+ MSCs in bone digests using fragments of 
femoral head bone (these sample are more readily avail­
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Figure 2. Assessment of cell abundance in Osteocel® 
as analyzed by histology, confocal microscopy and 
light microscopy. (A) Hematoxylin and eosin staining 
of decalcified fragments of Osteocel bone; compared 
with (B) control iliac crest bone; black filled arrows 
indicate presence of bone-lining cells, white filled arrows 
indicate embedded octeocytes. (C) Confocal microscopy 
indicating the presence of live (green) and dead (red) 
cells on the surface of Osteocel and (D) following the 
removal of bone reflected light signal showing more live 
cells embedded in the bone matrix (osteocytes), similar 
to (A). (E) Abundant osteocytes stained with Crystal 
Violet, original magnification ×40 and (F) ×100 indicated 
by white filled arrows.
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able compared with IC bone at our hospital). This was 
required because, specific for bone digests, we needed to 
account for small bone debris (absent in BM aspirates), 
which are auto­flourescent, giving false positive results. 
Since bone debris do not contain a nucleus/DNA, they 
could not be easily eliminated using common DNA­
based live/dead discriminatory dyes (7­AAD or DAPI) 
and, thus, could appear falsely as live cells. For the ana­
lysis of Osteocel, the exclusion of this debris was even 
more pertinent, as small DBM particles not removed by 
sieving could lead to incorrect estimation of MSC viabil­
ity and phenotype. We therefore used a new­generation 
of live/dead cell discrimination dyes that are based on 
a cell’s metabolic activity and compared staining with 
a standard gating method based on 7­AAD (Figure 4). 
Our new method clearly resolved live cells from bone 
debris (Figure 4A), which were otherwise included in the 
live gate of the conventional staining (Figure 4B). 
When the refined flow cytometry method was applied 
to Osteocel (n = 9); a clear population of CD45­CD271+ 
MSCs was evident with an average frequency of 30.4% 
(Figure 5A, left panel). These cells were also positive 
for CD73 (right panel), as well as CD90 and CD105 
(Figure 5C), consistent with their identity as MSCs 
[27,29,43]. The percentage of CD45+CD271­ hematopoi­
etic­lineage cells (HLCs) was very low (5.6%, range 
3.1–9.1%) (Figure 5A, left panel). 
In control age­matched IC bone samples (n = 6), 
CD45­CD271+ MSC frequency was an average 0.3%, 
significantly lower compared with Osteocel with 
an average 30.4% (Figure 5B, left panel). Similar to 
CD45­CD271+ MSCs in Osteocel, IC bone­MSCs were 
also positive for CD73, CD90 and CD105 (Figure 5C). 
The percentage of CD45+CD271­ HLCs in IC bone 
was on average 93% (range 89–95%) (Figure 5B, left 
panel). The CD45­CD271+ MSC purity in Osteocel 
was therefore an average 101­fold (p < 0.001) higher 
than in age­matched IC bone. Furthermore, an aver­
age ratio of MSCs to HLCs was 6:1 in Osteocel 
(MSC predominant), whereas in IC control bone, it 
was approximately 1:370 (HLC predominant). This 
clearly demonstrated the effective removal of HLCs 
(~2200­fold decrease) from Osteocel, and retention of 
the native MSC population. 
ImageStream ana lysis of Osteocel digests confirmed 
viable cell morphology of CD45­CD271+ events recov­
ered from the ‘live­cell’ gate, as well as their CD73­pos­
itivity (Figure 5D, top panel). Conversely, events recov­
ered from the ‘dead cells/debris’ region consisted of 
misshaped DBM or bone debris particles (Figure 5D, 
bottom panel). 
Finally, we compared the total number of 
CD45­CD271+ MSCs per gram of Osteocel bone 
with that of age­matched IC bone (Figure 5E). In con­
trol bone, a median of 1.3 million of CD45­CD271+ 
MSCs/g were present, consistent with previous estima­
tions [27]; in Osteocel this number was 0.53 million/g 
(difference not statistically significant).
BM aspirates are commonly used to ‘load’ syn­
thetic scaffolds with MSCs to enhance graft osteo­
inductivity [11–13]. The final set of experiments was 
designed to compare CD45­CD271+ MSC abundance 
in one gram of Osteocel with one ml of age­matched 
BM aspirate (Figure 5E). For this, we employed our 
previously­validated, single­platform flow cytom­
etry method to measure CD45­CD271+ MSCs in 
BM aspirates [35]. Total numbers of CD45­CD271+ 
MSCs/ml of BM aspirate were a median of 12,000/
ml (range 1126–28,210). Considering that approx­
imately 530,000 CD45­CD271+ MSCs were pres­
ent in 1 g of Osteocel, this would be equivalent to 
approximately 45 ml of good­quality, undiluted BM 
aspirate.
In summary, these flow cytometry results 
showed that similar to autograft IC bone, Osteo­
cel fragments contained a clear population of viable 
CD45­CD271+CD73+CD90+CD105+ MSCs. MSCs 
were found in Osteocel and IC bone at approximately 
0.5–1.3 million/g (based on median values), however 
Osteocel­MSCs were much purer (due to effective 
removal of HLCs). 
Osteocel® Iliac crest bone
D
ay 0
D
ay 21
D
ay 21
500 nm
Figure 3. Environmental scanning electron microscopy 
of stromal cell abundance (Day 0, top panels) and 
in vitro scaffold colonization (Day 21, middle and 
bottom panels) in Osteocel® and control iliac crest 
bone. White filled arrows show cell attachment points 
to bone, fat cells are indicated by dotted outline and 
black filled arrows.
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Discussion
Although autologous bone graft remains the most used 
graft material in orthopaedic surgery, it has significant 
limitations related to yield and harvesting techniques 
[15]. The clinical use of synthetic bone substitutes alone 
or loaded with BM aspirate [11–13] remains limited due 
to lack of level­one evidence and cost/benefit impli­
cations [15,44]. Despite being available in different for­
mulations [45], the use of traditional bone allografts 
on the other hand, has been limited due to known 
lack of osteogenic cells [15,45]. In this study we inves­
tigated a viable cellular bone allograft material Osteo­
cel, which has shown successful clinical outcomes 
[16,18–20,46–51], for the presence of MSCs, alongside the 
‘gold standard’ autograft IC bone and BM aspirate; 
this was done without any culture expansion, that 
is, in their clinically relevant condition. We detected 
MSC­specific signaling activity in Osteocel lyzates 
and extracted native CD45­CD271+ MSCs from 
Osteocel bone by enzymatic digestion. Using confocal 
and electron microscopy we documented the presence 
of viable osteocytes and bone­lining cells in Osteocel, 
with the latter being capable of extensive proliferation 
in situ before their egress onto plastic. We proved the 
MSC nature of Osteocel­derived cultures using stan­
dard ISCT criteria and for the first time showed their 
strong immunoregulatory capacity in co­culture with 
T­cells. Altogether our data indicate that Osteocel 
contains large numbers of viable osteogenic cells such 
as osteocytes and MSCs. These findings underpin 
how viable cellular bone allografts rich in MSCs could 
represent an effective alternative to autograft bone in 
orthopedics.
Despite its widespread clinical use and the lack of 
reported complications, a rigorous cellular characteri­
zation study of Osteocel has been very limited [20,21]. In 
comparison with two previous studies, which explored 
Osteocel­MSCs following cultivation, our work has 
been specifically focused on native MSCs resident in 
Osteocel; this was intended to reflect ‘the status’ of 
the graft material as it would be used clinically, and 
to directly compare it with autograft bone. In 2010, 
we showed that human bone­resident MSCs had the 
CD45­CD271+ phenotype [27]; which was later con­
firmed independently [28,38]. Having refined a flow­
cytometry method to eliminate bone debris/DBM 
from ana lysis, we now show that MSCs were not only 
viable, but also abundant in Osteocel, and their relative 
purity considerably exceeded that of autograft bone 
(101­fold). This increased purity was due to the effec­
tive depletion of immune cells/HLCs following pro­
cessing (<6% HLCs remaining), which was in stark 
contrast with autograft bone and BM aspirate where 
HLCs are the predominant population. 
In our previous study we did not observe any decline 
in CD45­CD271+ MSCs in aged donors, however a 
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Figure 4. Ana lysis of CD45-CD271+ multipotential stromal cell abundance in femoral head bone digests. (A) New 
live/dead binding dyes compared with (B) a traditional 7-AAD-based method. Far left panels: dot plots showing 
size distribution of all events (cells and debris). Middle left panels: gating on live cells (shown in red). Middle right 
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reduction in telomere lengths was found, potentially 
reflecting some MSC ‘ageing’ in vivo [27]. To its advan­
tage, Osteocel is obtained from younger donors with 
an average age of approximately 30 years [20]. Further­
more, gene expression of Osteocel samples demon­
strated the high expression of BMPs 2 and 6 and the 
reduction in inhibitors such Gremlin­1 [52]; this is 
likely to enhance the graft’s osteoinductivity and be 
particularly beneficial for patients with co­morbidities 
such as diabetes [53]. The overall transcript profile of 
the Osteocel resembled that of osteoblasts and MSCs 
[36,38,54] rather than fibroblasts (Table 1). Furthermore, 
our study showed that Osteocel also contained viable 
osteocytes; although these osteocytes could not be 
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Figure 5.  Analysis of CD45-CD271+ multipotential stromal cell abundance in enzymatic digests of Osteocel® 
and control age-matched iliac crest bone. (A) Analysis of CD45-CD271+ MSC abundance in enzymatic digests of 
Osteocel® and (B) control age-matched IC bone. (A & B) Left panels show the abundance of CD45-CD271+ MSCs 
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CD105 (n = 5 lots) and CD73 (n = 11 lots) expression on CD45-CD271+ cells from Osteocel (light blue bars) compared 
with IC bone control (dark blue bars; n = 4, four and five donors, respectively). (D) ImageStream™ morphological 
ana lysis of CD45-CD271+ in a representative Osteocel digests collected in the ‘Live cell’ gate (top) and 
debris/demineralized bone matrix gate (bottom). (E) Absolute numbers of CD45-CD271+ MSCs in Osteocel, control 
IC bone and bone marrow aspirate per 1 g (or 1 ml) indicating inferiority of bone marrow aspirate compared with 
both IC bone and Osteocel (both significant at p < 0.0001). Error bars represent SD. 
IC: Iliac crest; MSC: Multipotential stromal cell; HLC: Hemopoietic lineage cells.
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extracted from the mineralized tissue with collagenase, 
they could represent important graft constituents, 
since they are the mechanotransducers that modulate 
bone metabolism according to Wolff ’s Law [55,56]. 
The ease of BM aspirate collection and availability 
of concentration devices, allowing MSC enrichment 
five­ to seven­fold [57,58], have made BM aspirate an 
attractive material in orthopedics [5,59–61]. Loading 
bone substitute scaffolds with BM aspirate is becom­
ing common in spinal surgery in particular [11–13]. In 
this study we directly compared the number of MSCs 
in one gram of cellular bone allograft with 1 ml of BM 
aspirate. Our calculations reveal that even after con­
centration [58] the density of loaded MSCs is unlikely 
to match the quantity that can be delivered in 1 g of 
Osteocel and that approximately 45 ml of carefully 
collected BM aspirate would be needed to achieve the 
same number of MSCs as present in 1 gram of Osteo­
cel. Harvesting these volumes of BM would require 
multiple needle insertion points, as shown recently 
[62], and may cause further discomfort and prolong 
recovery for the patient. 
In respect to autograft IC bone, our study used 
enzymatic release and flow cytometry techniques to 
evaluate the total numbers of MSCs/gram of bone; we 
acknowledge however that this part of our study was 
limited by the availability of enough autograft bone 
that could be donated to perform the complex flow­
cytometry measurements. Additionally, we acknowl­
edge that other ways of enumerating bone­resident 
MSCs have been employed in the past, such as bone 
fragmentation followed by a conventional colony­
forming unit­fibroblast assay of passively­released cells 
[58]. However, enzymatic release has been shown to be 
more efficient than fragmentation/passive release [63]. 
Additionally, flow cytometry­based techniques are 
believed to be more accurate for MSC enumeration 
than CFU­F assay, since the latter is highly subjec­
tive and prone to under­estimating MSC numbers as 
a result of sub­optimal cell seeding densities or serum 
lots variations [35,43,64].
Conclusion
In summary, we enumerated resident MSCs in IC 
autograft bone, BM aspirate and in a commercially 
available cellular bone allograft where HLCs were spe­
cifically depleted. Our data supports the osteogenic 
and immunoregulatory properties of viable bone allog­
rafts, which may be important in a variety of regen­
erative medical applications. Additionally, it comple­
ments the published clinical use of viable bone allog­
rafts in orthopedics and highlights the value of bone 
as an abundant source of native MSCs for a variety of 
regenerative medicine applications.
Future perspective
Besides its practical value to orthopedics, we believe 
that our work has implications for the study of native 
MSCs in diseased bone, particularly in areas of avascu­
lar necrosis or in BM lesions of osteoarthritis patients. 
For such studies, MSCs can be enzymatically extracted 
from patients’ femoral heads, and their viability and 
phenotypes accurately evaluated using our novel flow­
cytometry technique or cell sorting. Secondly, fur­
ther study of viable allografts such as Osteocel offers 
a technological solution to investigate the differential 
molecular profiles of human MSCs, proximal to bone, 
with that of osteocytes; so far only studied in animal 
models [65–67]. This could reveal novel human MSC­ 
and osteocyte­specific molecules that could be further 
explored as potential targets for the treatment of a 
systemic bone disease such as osteoporosis. Inhibition 
of one such osteocyte­specific molecule, Sclerostin, 
has been recently hailed as ‘potential breakthrough 
in osteoporosis therapeutics’ [68], and other potential 
candidates could follow. From a clinical perspective, 
future animal studies are needed to test the mechanism 
of action of bone­anchored MSCs in cellular allografts 
such as Osteocel following graft implantation, as well 
as any potential reactions by host immune systems [69] 
against Osteocel­MSCs following their differentiation 
to bone. For instance, whether these MSCs participate 
in new bone formation via their direct differentiation, 
similar to allogeneic MSCs loaded on ceramic scaffolds 
[70], or whether they serve more as immunoregulators 
forming a favorable niche for migration and appropri­
ate differentiation of host MSCs remains to be estab­
lished. In this context, our findings showing strong 
CXCL12 gene expression (gene encoding the chemok­
ine SDF­1, involved in stem cell migration [71,72]) in 
this cellular allograft suggests that indeed, such cellu­
lar allografts may possess a chemotactic capacity; this 
should be further investigated.
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